Hematopoietic stem cells are multipotent stem cells which give rise to all other blood cell types. A Hematopoietic stem cell mobilizer inhibits the CXCR4 chemokine receptor, blocking the binding of its ligand.
Regular Websites
The American Journal of Hematology and Oncology publishes a news article about Mozobil which includes its pharmacologic class, active ingredient, indication and results of clinical trials. Also contains an area for readers to comment. - AJHO: Mozobil
http://www.ajho.com/mozobil/article/130250/
Hematopoietic Stem Cell Mobilizer Approved
Peer review of Mozobil and its approval for mobilization of hematopoietic stem cells for autologous transplantation in patients with non-Hodgkins lymphoma and multiple myeloma. - Hematopoietic Stem Cell Mobilizer Approved
http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Plerixafor-Mozobil-Hematopoietic-stem-cell-mobiliz/ArticleStandard/Article/detail/579382
Consists of data regarding apheresis success in non-Hodgkin's lymphoma and multiple myeloma patients. - Mozobil
http://www.mozobil.com/